Study Title
MyeChild-01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy
Protocol ID
RG_14-088 (MyeChild-01)
Condition/s
Acute Myeloid Leukaemia (AML)
Diagnosis Stage
New diagnosis
Sponsor
Australian and New Zealand Children's Haematology Oncology Group
University of Birmingham
University of Birmingham
Collaborators
Assistance Publique - Hôpitaux de Paris
Cancer Research UK
National Cancer Institute, France
Pfizer
Cancer Research UK
National Cancer Institute, France
Pfizer
Links
Trial Status
Closed to Recruitment
Study Type
Treatment
Phase
Phase 3
Age Eligibility
up to 18 years
International registry ID's
NCT02724163
| Study Title | MyeChild-01: International Randomised Phase III Clinical Trial in Children with Acute Myeloid Leukaemia – Incorporating an Embedded Dose Finding Study for Gemtuzumab Ozogamicin in Combination with Induction Chemotherapy |
|---|---|
| Protocol ID | RG_14-088 (MyeChild-01) |
| Disease (Sub Disease) | Acute Myeloid Leukaemia (AML) |
| Diagnosis Stage | New diagnosis |
| Sponsor | Australian and New Zealand Children's Haematology Oncology Group/ University of Birmingham |
| Collaborators | Assistance Publique - Hôpitaux de Paris/ Cancer Research UK/ National Cancer Institute, France/ Pfizer |
| Links | https://clinicaltrials.gov/ct2/show/NCT02724163 |
| Trial Status | Closed to Recruitment |
| Trial Open Date | 04/07/2018 |
| Study Type | Treatment |
| Phase | Phase 3 |
| Age Eligibility | up to 18 years |
| International registry ID's | NCT02724163 |